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 CADISS: a feasibility trial that answered its question
Anticoagulation after ischaemic stroke was a topic 
of major controversy for decades until a series of 
randomised clinical trials consistently showed no net 
beneﬁ t of heparin or warfarin compared with aspirin.1,2 
Any reduction in the risk of recurrent ischaemic 
stroke was oﬀ set by an increase in risk of intracerebral 
haemorrhages. One cause of stroke for which the eﬀ ect 
of anticoagulation remains unclear is cervical artery 
dissection. The classic dogma was that a tear in the 
intima leads to formation of a ﬁ brin-rich thrombus and 
poses a very high risk of artery-to-artery embolism or 
occlusion, making early anticoagulation the treatment 
of choice.3 Furthermore, this risk was thought to persist 
for months until the artery heals. Countless experts 
recommended this approach, but acknowledged the 
lack of dependable data.  
Observational studies have yielded conﬂ icting 
results.4–6 A systematic review and meta-analysis7 
of 36 observational studies showed no signiﬁ cant 
diﬀ erences between anticoagulation and antiplatelet 
treatment for clinical outcomes or risk of recurrent 
stroke. For doctors inclined to use anticoagulation, 
the point estimates suggested a potential beneﬁ t. For 
those who were sceptical, the neutral results provided 
no compelling reason to use anything other than 
antiplatelet treatment. American Heart Association/
American Stroke Association guidelines8,9 left open 
both options, suggesting that either approach is 
reasonable for 3–6 months (class IIa, level B, a weak 
recommendation), although these guidelines otherwise 
strongly recommend antiplatelet treatment over 
anticoagulation for acute management and secondary 
prevention after non-cardioembolic stroke (class I, 
level A, their highest endorsement).
The Cervical Artery Dissection in Stroke Study 
(CADISS) was the ﬁ rst randomised clinical trial to 
compare anticoagulation with antiplatelet treatment 
for cervical artery dissection. It was designed as a 
pilot study, aiming to estimate the risk of recurrent 
stroke reliably and establish whether a deﬁ nitive trial 
would be feasible.  The main results, published in The 
Lancet Neurology,10 are much the same as those from 
the other anticoagulation trials—any reduction in 
ischaemic stroke was counterbalanced by an increase 
in haemorrhages. However, events were rare, with 
only four ischaemic strokes (three in the antiplatelet 
group and one in the anticoagulant group) and one 
subarachnoid haemorrhage (in the anticoagulant 
group) among the 250 participants. The rarity of events 
meant that the study did not answer the question of 
which strategy was superior overall, but that was not 
expected from this pilot trial. 
Nevertheless, CADISS informs both clinical practice 
and clinical research. First, dissection might be harder 
to diagnose than one might think. About 20% of 
dissections in this trial could not be conﬁ rmed by central 
review of vascular imaging. Perhaps other factors, 
including age or localised pain, led to a presumptive 
diagnosis without deﬁ nitive imaging data. Diagnoses 
need to be improved for future studies of treatment for 
dissection. Second, the overall risk of stroke was low, 
suggesting that dissection might be less of a problem 
than traditionally thought. The risk of stroke was 
zero for patients who presented with anything other 
than an initial stroke. Although representing only a 
subset of patients, this very low risk is consistent with 
observational data4 and suggests that anticoagulation 
should not routinely be recommended in this context. 
Third, all stroke events occurred in the ﬁ rst 10 days after 
randomisation. This would suggest that patients who 
present late are probably another very low risk group. 
Additionally, for those who still prefer anticoagulation 
even after reading the CADISS results, the duration of 
such treatment might be shortened to less than several 
months.  
Some questions remain unanswered. Because of 
practical considerations, CADISS enrolled patients up 
to 7 days after onset of symptoms, or even longer if 
they presented with stroke and prodromal symptoms. 
Patients with very early recurrent strokes might 
therefore never have been enrolled, so there could be 
an unseen higher risk group for which data are lacking. 
Further, radiographic features of dissection, both at the 
time of diagnosis and during the healing process, might 
be associated with subsequent stroke risk.  
The CADISS investigators estimated that a future 
trial with a similar design would need to enrol 
10 000 participants to detect a 1% diﬀ erence in 
occurrence of ipsilateral stroke or death or major 
bleeding between anticoagulation and antiplatelet 
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Stroke is a leading cause of death and disability 
worldwide, with few eﬀ ective acute treatments. For 
patients with ischaemic stroke who present promptly 
to a properly equipped hospital and receive intravenous 
alteplase within 4·5 h, chance of regaining excellent 
functional outcome is greatly increased.1 The treatment 
eﬀ ect decays rapidly with time, and patients with 
larger clot burden or more severe strokes often do not 
respond to alteplase. Many attempts have been made to 
determine whether alternative drugs or devices might 
be more eﬀ ective than alteplase, but breaking up arterial 
clots has proven hard to do.
Pilot studies suggested that tenecteplase, which is 
more ﬁ brin-speciﬁ c and easier to deliver, might be an 
alternative to alteplase.2 However, as reported in The 
Lancet Neurology, the ATTEST study  failed to show 
a diﬀ erence between tenecteplase versus alteplase 
when administered within 4·5 h of stroke onset.3 
52 patients were randomly assigned to alteplase and 
52 to tenecteplase and were treated based on eligibility 
criteria for traditional intravenous alteplase and a 
non-contrast head CT; they subsequently underwent 
attempted CT perfusion imaging and CT angiography. 
The primary endpoint—the percentage of initial 
territory-at-risk on CT perfusion that did not progress 
to infarct on follow-up non-contrast CT—showed no 
signiﬁ cant diﬀ erences between the two drugs in degree 
of penumbral salvage (68% [SD 28] with tenecteplase 
treatment. If the population could be restricted to 
those who present with stroke, are correctly and rapidly 
diagnosed, and are then enrolled and treated early, 
maybe only half or even a quarter as many participants 
would be needed. Testing of newer oral anticoagulants, 
which are probably safer and easier to manage than 
warfarin, should also be considered.11 
Should investigators forge ahead? Despite having 
outstanding sites in the UK and Australia, and allowing 
for a generous time window, recruitment into CADISS 
occurred at an average of one participant per centre 
per year. A study of 5000 participants might require 
500 sites and 10 years to complete recruitment. 
The primary objective of CADISS was to establish 
the feasibility of a deﬁ nitive clinical trial comparing 
antiplatelet treatment with anticoagulation for patients 
with cervical artery dissection. The investigators 
achieved their objective—that pivotal trial is not feasible 
at present. Antiplatelet treatment seems to be the safer, 
more convenient, and less costly default treatment 
for now, but eﬀ orts should continue to understand 
the pathophysiology of dissection and to identify and 
characterise the rare patients who remain at risk for 
subsequent stroke.
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